Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis

Journal of Immunology

Volumn 191, Issue 10, 2013, Pages 5074-5084

  Ji, Niannian ^a   Somanaboeina, Animesh ^a   Dixit, Aakanksha ^a   Kawamura, Kazuyuki ^a   Hayward, Neil J ^b   Self, Christopher ^c   Olson, Gary L ^c   Forsthuber, Thomas G ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b Daiamed   (United States)

^c Provid Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; HLA DR9 ANTIGEN; IMMUNOLOGIC AGENT; PV 267; UNCLASSIFIED DRUG; VALINE; HLA DR2 ANTIGEN; MYELIN BASIC PROTEIN; PEPTIDE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME STABILITY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; ANIMAL; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; T LYMPHOCYTE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HLA-DR2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; PEPTIDES; T-LYMPHOCYTES;

EID: 84887486334     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300407     Document Type: Article

References (48)

1. Krogsgaard, M., K. W. Wucherpfennig, B. Canella, B. E. Hansen, A. Svejgaard, J. Pyrdol, H. Ditzel, C. Raine, J. Engberg, and L. Fugger. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.[Published erratum appears in 2003 J. Exp. Med.197:947]. J. Exp. Med. 191:1395-1412.
2. Valli, A., A. Sette, L. Kappos, C. Oseroff, J. Sidney, G. Miescher, M. Hochberger, E. D. Albert, and L. Adorini. 1993. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 91:616-628.
3. Vergelli, M., M. Kalbus, S. C. Rojo, B. Hemmer, H. Kalbacher, L. Tranquill, H. Beck, H. F. McFarland, R. De Mars, E. O. Long, and R. Martin. 1997. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J. Neuroimmunol. 77:195-203.
4. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, et al. 1995. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiplesclerosis: results of a phase-Iii multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276.
5. Duquette, P., M. Girard, L. Despault, R. Dubois, R. L. Knobler, F. D. Lublin, L. Kelley, G. S. Francis, Y. Lapierre, J. Antel, et al; The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661.
6. Ebers, G. C., G. Rice, J. Lesaux, D. Paty, J. Oger, D. K. B. Li, S. Beall, V. Devonshire, S. Hashimoto, J. Hooge, et al. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504.
7. Whitacre, C. C., I. E. Gienapp, A. Meyer, K. L. Cox, and N. Javed. 1996. Oral tolerance in experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 778:217-227.
8. Weiner, H. L., G. A. Mackin, M. Matsui, E. J. Orav, S. J. Khoury, D. M. Dawson, and D. A. Hafler. 1993. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259:1321-1324.
9. Brod, S. A., A. Al-Sabbagh, R. A. Sobel, D. A. Hafler, and H. L. Weiner. 1991. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens. IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. Ann. Neurol. 29:615-622.
10. Ruiz, P. J., H. Garren, D. L. Hirschberg, A. M. Langer-Gould, M. Levite, M. V. Karpuj, S. Southwood, A. Sette, P. Conlon, and L. Steinman. 1999. Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. J. Exp. Med. 189:1275-1284.
11. Vergelli, M., B. Hemmer, U. Utz, A. Vogt, M. Kalbus, L. Tranquill, P. Conlon, N. Ling, L. Steinman, H. F. McFarland, and R. Martin. 1996. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur. J. Immunol. 26:2624-2634.
12. Bourdette, D. N., Y. K. Chou, R. H. Whitham, J. Buckner, H. J. Kwon, G. T. Nepom, A. Buenafe, S. A. Cooper, M. Allegretta, G. A. Hashim, et al. 1998. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. J. Immunol. 161:1034-1044.
13. Bourdette, D. N., E. Edmonds, C. Smith, J. D. Bowen, C. R. G. Guttmann, Z. P. Nagy, J. Simon, R. Whitham, J. Lovera, V. Yadav, et al. 2005. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult. Scler. 11:552-561.
14. Link, J. M., C. M. Rich, M. Korat, G. G. Burrows, H. Offner, and A. A. Vandenbark. 2007. Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clin. Immunol. 123:95-104.
15. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman; The Altered Peptide Ligand in Relapsing MS Study Group. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 6:1176-1182.
16. Bloomgren, G., S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, A. Natarajan, S. Lee, T. Plavina, J. V. Scanlon, A. Sandrock, and C. Bozic. 2012. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366:1870-1880.
17. Kappos, L., J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, and E. W. Radue; FTY720 D2201 Study Group. 2006. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355:1124-1140.
18. O'Connor, P., G. Comi, X. Montalban, J. Antel, E. W. Radue, A. De Vera, H. Pohlmann, and L. Kappos; FTY720 D2201 Study Group. 2009. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72:73-79.
19. O'Connor, P. W., D. Li, M. S. Freedman, A. Bar-Or, G. P. A. Rice, C. Confavreux, D. W. Paty, J. A. Stewart, and R. Scheyer; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. 2006. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894-900.
20. O'Connor, P., J. S. Wolinsky, C. Confavreux, G. Comi, L. Kappos, T. P. Olsson, H. Benzerdjeb, P. Truffinet, L. Wang, A. Miller, and M. S. Freedman; TEMSO Trial Group. 2011. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365:1293-1303.
21. Coles, A. J., D. A. S. Compston, K. W. Selmaj, S. L. Lake, S. Moran, D. H. Margolin, K. Norris, and P. K. Tandon; CAMMS223 Trial Investigators. 2008. Alemtuzumab vs.interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359:1786-1801.
22. Gold, R., L. Kappos, D. L. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, C. Tornatore, M. T. Sweetser, M. Yang, S. I. Sheikh, and K. T. Dawson; DEFINE Study Investigators. 2012. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367:1098-1107.
23. Schmidt, H., D. Williamson, and A. Ashley-Koch. 2007. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 165:1097-1109.
24. Jardetzky, T. S., J. H. Brown, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1996. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl. Acad. Sci. USA 93:734-738.
25. Smith, K. J., J. Pyrdol, L. Gauthier, D. C. Wiley, and K. W. Wucherpfennig. 1998. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188:1511-1520.
26. Ishioka, G. Y., L. Adorini, J. C. Guery, F. C. Gaeta, R. La Fond, J. Alexander, M. F. Powell, A. Sette, and H. M. Grey. 1994. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo: implications for therapeutic potential of MHC-blocking peptides. J. Immunol. 152:4310-4319.
27. Kawamura, K., K. A. McLaughlin, R. Weissert, and T. G. Forsthuber. 2008. Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice. J. Immunol. 181:3202-3211.
28. Madsen, L., N. Labrecque, J. Engberg, A. Dierich, A. Svejgaard, C. Benoist, D. Mathis, and L. Fugger. 1999. Mice lacking all conventional MHC class II genes. Proc. Natl. Acad. Sci. USA 96:10338-10343.
29. Hofstetter, H. H., C. L. Shive, and T. G. Forsthuber. 2002. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169:117-125.
30. Fleming, K. K., J. A. Bovaird, M. C. Mosier, M. R. Emerson, S. M. Le Vine, and J. G. Marquis. 2005. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170:71-84.
31. Liu, L., G. J. Graham, A. Damodaran, T. Hu, S. A. Lira, M. Sasse, C. Canasto-Chibuque, D. N. Cook, and R. M. Ransohoff. 2006. Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis. J. Immunol. 177:17-21.
32. Bolin, D. R., A. L. Swain, R. Sarabu, S. J. Berthel, P. Gillespie, N. J. S. Huby, R. Makofske, L. Orzechowski, A. Perrotta, K. Toth, et al. 2000. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules: design, structure-activity relationships, and X-ray crystal structures. J. Med. Chem. 43:2135-2148.
33. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215-221.
34. Ito, K., H. J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D. R. Bolin, R. Arceo, R. Campbell, et al. 1996. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183:2635-2644.
35. Buttinelli, C., A. Clemenzi, G. Borriello, F. Denaro, C. Pozzilli, and C. Fieschi. 2007. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur. J. Neurol. 14:1281-1287.
36. Charach, G., I. Grosskopf, and M. Weintraub. 2008. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 77:198-200.
37. Turaka, K., and J. S. Bryan. 2012. Does fingolimod in multiple sclerosis patients cause macular edema? J. Neurol. 259:386-388.
38. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167-1175.
39. Link, J., I. Kockum, A. R. Lorentzen, B. A. Lie, E. G. Celius, H. Westerlind, M. Schaffer, L. Alfredsson, T. Olsson, B. Brynedal, et al. 2012. Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS One 7:e36779.
40. Stratikos, E., D. C. Wiley, and L. J. Stern. 2004. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain. J. Immunol. 172:1109-1117.
41. Anders, A. K., M. J. Call, M. S. Schulze, K. D. Fowler, D. A. Schubert, N. P. Seth, E. J. Sundberg, and K. W. Wucherpfennig. 2011. HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat. Immunol. 12:54-61.
42. Lehmann, P. V., T. Forsthuber, A. Miller, and E. E. Sercarz. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155-157.
43. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:75-85.
44. Brown, S. L., M. H. Greene, S. K. Gershon, E. T. Edwards, and M. M. Braun. 2002. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46:3151-3158.
45. Geborek, P., A. Bladström, C. Turesson, A. Gulfe, I. F. Petersson, T. Saxne, H. Olsson, and L. T. H. Jacobsson. 2005. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64:699-703.
46. Siegel, C. A., S. M. Marden, S. M. Persing, R. J. Larson, and B. E. Sands. 2009. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7:874-881.
47. Hansen, T., A. Skytthe, E. Stenager, H. C. Petersen, H. Brønnum-Hansen, and K. O. Kyvik. 2005. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 11:504-510.
48. Baranzini, S. E., J. Mudge, J. C. Van Velkinburgh, P. Khankhanian, I. Khrebtukova, N. A. Miller, L. Zhang, A. D. Farmer, C. J. Bell, R. W. Kim, et al. 2010. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464:1351-1356.